Loading
Runs the UCLA theranostics trials that test PSMA imaging against conventional scans and lutetium against chemotherapy.
Jeremie Calais is Associate Professor and Director of the Clinical Research Program in the Ahmanson Translational Theranostics Division at UCLA, part of the UCLA Jonsson Comprehensive Cancer Center. A nuclear medicine physician specialising in PSMA PET and radioligand therapy, he leads prospective PSMA PET and PSMA radioligand therapy trials, including the head-to-head comparison of PSMA PET with fluciclovine PET and dosimetry research. His papers include the Lancet Oncology comparative imaging trial of 18F-fluciclovine and 68Ga-PSMA-11 PET-CT in early biochemical recurrence after prostatectomy and the Journal of Nuclear Medicine RESIST-PC phase 2 trial of 177Lu-PSMA-617 in the UCLA cohort. His work centres on prostate cancer theranostics.
Shares UCLA Jonsson Comprehensive Cancer Center, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares Journal of Nuclear Medicine, PSMA, Radioligand therapy (beta emitters).
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares Journal of Nuclear Medicine, PSMA, Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.